MucoMAX®
Oral mucosal immunity medicine development platform technology
- Core source technology
for immunotherapy - Potential to develop
new vaccines - Optimized
treatment effects - Stability and cost
competitiveness
- Securing a comparative edge in terms of "safety" and "cost competitiveness" over existing vaccine development technologies
- Next-generation core source technology for immunotherapy that includes all of the advantages of antibody drugs, cell therapy products, and gene medicines
- Technology with an extremely great “scalability" capable of developing new vaccines in a short period of time by using genetic recombination technologies
Platform technology for the development of oral treatment vaccines and preventive vaccines
- Induces antigen-specific immunities by absorbing antigens (entire protein or some peptides) into a body with lactic acid bacteria as its transporter : Induces antigen (target)-specific CTL (Cytotoxic T Lymphocyte) immunities or antibodies (Ab)
- Technology with immunological characteristics that prevents and treats diseases or symptoms by inducing voluntary antigen-antibody reactions inside a body to neutralize or eliminate target proteins and. by increasing the activation of cytotoxicity, to remove heteromorphic cells
Medicine under development and diseases to be treated
BLS-M07: Treatment vaccine for cervical cancer BLS-M22: Treatment vaccine for DMD
Pursuit of pipeline extension
- New candidate medicine substances under development to replace follow-up antibody drugs, including medicine for the treatment of rare diseases
- Treatment vaccines for solid cancers including female cancers (cancer immunotherapy) and for metabolic diseases, etc.